Alogliptin May Be Associated With Lower Fracture Risk Compared With Linagliptin, Saxagliptin
The DPP-4 inhibitor alogliptin may be associated with a lower risk for bone fracture compared with linagliptin and saxagliptin.
Sciatic nerve block may represent an effective complement to femoral nerve block for total knee arthroplasty.
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.